Limited place for plasma monitoring of new antiepileptic drugs in clinical practice

Medical Science Monitor

Volumn 14, Issue 10, 2008, Pages

  Striano, Salvatore ^a   Striano, Pasquale ^a,b   Capone, Domenico ^a   Pisani, Francesco ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antiepileptic drugs; Plasma monitoring; Side effects; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHINYLESTRADIOL; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE OF SIDE EFFECTS; ANOREXIA; ATAXIA; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; COGNITIVE DEFECT; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG TOLERABILITY; EPILEPSY; EYE MOVEMENT DISORDER; HAND TREMOR; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; LIVER DISEASE; MORNING DOSAGE; NAUSEA; NONHUMAN; NYSTAGMUS; RASH; REVIEW; SEIZURE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VISUAL FIELD DEFECT; WEIGHT REDUCTION;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DRUG MONITORING; EPILEPSY; FEMALE; HUMANS; PREGNANCY;

EID: 54249145765     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Patsalos PN, Berry DJ, Bourgeois BFD et al: Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 2008; 49: 1239-76
2. nd ed.) Blackwell Science Ltd Oxford, 2004; 139-60
3. Shorvon SD, Chadwick D, Galbraith AW, Reynolds EH: One drug for Epilepsy. BMJ, 1978; 1: 474-76
4. Landmark CJ: Targets for antiepileptic drugs in the synapse. Med Sci Monit, 2007; 13(1): RA1-7
5. French JA, Gidal BE: Antiepileptic drug interactions. Epilepsia, 2000; 41(Suppl.8): S30-S36
6. Johannessen SL, Battino D, Berry DJ et al: Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit, 2003; 25: 347-63
7. Neels HM, Sierens AC, Naelaerts K et al: Therapeutic drug monitoring of old and newer antiepileptic drugs. Clin Chem Lab Med, 2004; 42: 1228-55
8. Tomson T, Battino D: Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and puerperium. Clin Pharmacokinet, 2007; 46: 209-19
9. Tomson T, Dahl ML, Kimland E: Therapeutic monitoring of antiepileptic drugs for Epilepsy. The Cochrane Collaboration, 2007; 1: CD002216
10. Camfield P, Camfield C: Monitoring for adverse effects of antiepileptic drugs. Epilepsia, 2006; 47(Suppl.1): S31-34
11. Glauser TA, Pippenger CE: Controversies in blood-level monitoring: Reexamining its role in the treatment of Epilepsy. Epilepsia, 2000; 41(Suppl.8): S6-15
12. Froscher W, Schier KR, Hoffmann M et al: Topiramate: a prospective study on the relationship between concentration, dosage and adverse effects in epileptic patients on combination therapy. Epileptic Disorder, 2005; 7: 237-48
13. Striano S, Striano P, Di Nocera P et al: Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with Epilepsy on high-dose Oxcarbazepine therapy. Epilepsy Res, 2006; 69: 170-76
14. Barcs G, Walker EB, Elger CE et al: Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial Epilepsy. Epilepsia, 2000; 41: 1597-607
15. nd ed.) Blackwell Science Ltd Oxford, 2004; 451-60
16. Battino D, Croci D, Granata T et al: Changes in unbound and in total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine. Ther Drug Monit, 1992; 14: 376-79
17. Chaisewikul R, Privitera MD, Hutton JL, Marson AG: Levetiracetam addon for drug-resistant localization-related (partial) Epilepsy (Cochrane review). Cochrane Database Syst Rev, 2001; 1: CD001901
18. Krauss GL, Betts T, Abou-Khalil B et al: Levetiracetam treatment of idiopathic generalized Epilepsy. Seizure, 2003; 12: 617-20
19. Lynch BA, Lambeng N, Nocka K et al: The synaptic vescicle protein SV2A is the binding site for the antiepileptic drug Levetiracetam. Proc Natl Acad Sci USA, 2004; 101: 9861-66
20. Patsalos PN, Ghattaura S, Ratnaraj N, Sander JW: In situ metabolism of Levetiracetam in blood patients with Epilepsy. Epilepsia, 2006; 47: 1818-21
21. nd ed.) Blackwell Science Ltd Oxford, 2004; 443-50
22. Pennell PB: Is breast milk the best for babies of mothers on levetiracetam? Epilepsy Curr, 2006; 6: 22-24
23. Curatolo P, Bombardieri R, Cerminara C: Current management for epilepsy in tuberous sclerosis complex. Curr Opin Neurol, 2006; 19: 119-23
24. Patsalos PN, Duncan JN: The pharmacology and pharmacokinetics of Vigabatrin. Rev Contemp Pharmacother, 1995; 6: 447-56
25. nd ed.) Blackwell Science Ltd Oxford, 2004; 540-47
26. nd ed.) Blackwell Science Ltd Oxford, 2004; 507-14
27. Striano S, Striano P, Boccella P et al: Tiagabine in glial tumors. Epilepsy Res, 2002; 49: 81-85
28. th ed.) Lippincott Williams & Wilkins, Philadelphia, 2002; 681-90
29. Williams J, Bialer M, Johannessen SJ et al: Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia, 2003; 44: 40-45
30. Gee NS, Brown JP, Dissanayake VU et al: The novel anticonvulsant drug, gabapentin (Neurontin) binds to the alpha delta 2 subunit of a calcium channel. J Biol Chem, 1996; 271: 5768-76
31. Taylor CP, Angelotti T, Fauman E: Pharmacology and mechanism of action of pregabalin: The calcium channel alpha(2)-delta subunit as a target for antiepileptic drug discovery. Epilepsy Res, 2007; 73: 137-50
32. nd ed.) Blackwell Science Ltd Oxford, 2004; 418-24
33. Berry D, Millington C: Analysis of Pregabalin at therapeutic concentrations in human plasma/serum by reversed phase HPLC. Ther Drug Monitor, 2005; 27: 451-56
34. nd ed.) Blackwell Science Ltd Oxford, 2004; 403-9
35. Wagner ML, Graves NM, Leppik IE et al: The effect of felbamate on valproic acid disposition. Clin Phrmacol Ther, 1994; 5: 494-502
36. Siegel H, Kelley K, Stertz B et al: The efficacy of Felbamate as add-on therapy to Valproic acid in Lennox-Gastaut syndrome. Epilepsy Res, 1999; 34: 91-97
37. nd ed.) Blackwell Science Ltd Oxford, 2004; 425-42
38. Pisani F, Oteri G, Russo MF et al: The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia, 1999; 40: 1141-46
39. Messenheimer J, Mullens EL, Giorgi L, Young F: Safety review of adult clinical trial experience with lamotrigine. Drug Saf, 1998; 18: 281-96
40. Besag FMC, Berry DJ, Pool F et al: Carbamazepine toxicity with Lamotrigine: Pharmacokinetic or Pharmakodynamic interaction? Epilepsia, 1998; 39: 183-87
41. Warner T, Patsalos PN, Prevett M et al: Lamotrigine induced carbamazepine toxicity: an interaction with carbamazepine-10,11 epoxide. Epilepsy Res, 1992; 11: 147-50
42. nd ed.) Blackwell Science Ltd Oxford, 2004; 515-27
43. Ferrari AR, Guerrini R, Gatti G et al: Influence of dosage, age and comedication on plasma Topiramate concentrations in children and adults with severe Epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monitoring, 2003; 25: 700-8
44. Stephen LJ, Sills GJ, Brodie MJ: Topiramate in refractory Epilepsy: a prospective observational study. Epilepsia, 2000; 41: 977-80
45. Lee HW, Jung DK, Suh CK et al: Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: A 1-year follow-up. Epilepsy Behav, 2006; 8: 736-41
46. Lagae L: Cognitive side effects of anti-epileptic drugs. The relevance in childhood epilepsy. Seizure, 2006; 15: 235-41
47. Reife RR, Pledger G, Doose D et al: Topiramate: PK/PD analyses. Epilepsia, 1995; 36(Suppl.3): S152
48. Nagel BJ, Brewer VR, Phelphs SJ: Cognitive and behavioural side effects associated with topiramate. J Pediatr Pharmacol Ther, 2001; 6: 258-70
49. Contin M, Riva R, Albani F et al: Topiramate therapeutic monitoring in patients with Epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monitoring, 2002; 24: 332-37
50. Zanotta N, Raggi ME, Radice L et al: Clinical experience with topiramate and serum levels in patients with Epilepsy. Seizure, 2006; 15: 86-92
51. Mula M, Trimble MR, Thompson P, Sander JW: Topiramate and word-finding difficulties in patients with epilepsy. Neurology, 2003; 60: 1104-7
52. Leppik IE, Willmore LJ, Homan RW et al: Efficacy and safety of Zonisamide: results of a multicenter study. Epilepsy Res, 1993; 14: 165-73
53. nd ed.) Blackwell Science Ltd Oxford, 2004; 548-59
54. th ed.). Lippincott Williams & Wilkins, Philadelphia, 2002; 867-72
55. Berent S, Sackellares JC, Giordani B et al: Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia, 1987; 28: 61-67
56. Perucca E: Clinically relevant drug interactions with antiepileptic drugs. British J Clin Pharmacol, 2005; 61: 246-55
57. Woo E, Chan YM, Yu YL et al: If a well-stabilized epileptic patients has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia, 1988; 29: 129-39
58. Buchtal F, Svensmak O: Aspects of the pharmacology of phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of Epilepsy. Epilepsia, 1960; 1: 373-84
59. Richens A, Davidson DL, Cartlidge NEF, Easter DJ: A multicentre comparative trial of sodium valproate and carbamazepine in adult onset Epilepsy. J Neurol Neurosurg Psychiat, 1994; 57: 682-87
60. Loscher W, Schmid D: Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia, 2006; 47: 1253-84
61. Eadie MJ: Indications for plasma drug monitoring in patients with epilepsy. Implications for reducing costs. Pharmacoeconomics, 1997; 11(4): 343-49
62. Aldenkamp AP, De Krom M, Reijs R: Newer antiepileptic drugs and cognitive issues. Epilepsia, 2003; 44(Suppl.4): S21-29
63. Ortinski P, Meador KJ: Cognitive side effects of antiepileptic drugs. Epilepsy Behav, 2004; 5(Suppl.1): S60-65